Metastatic disease remains the primary cause of death for patients with breast cancer. The different steps of the metastatic cascade rely on reciprocal interactions between cancer cells and their microenvironment. Within this local microenvironment and in distant organs, immune cells and their mediators are known to facilitate metastasis formation 1, 2 . However, the precise contribution of tumourinduced systemic inflammation to metastasis and the mechanisms regulating systemic inflammation are poorly understood. Here we show that tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis. We mechanistically demonstrate that interleukin (IL)-1b elicits IL-17 expression from gamma delta (cd) T cells, resulting in systemic, granulocyte colony-stimulating factor (G-CSF)-dependent expansion and polarization of neutrophils in mice bearing mammary tumours. Tumour-induced neutrophils acquire the ability to suppress cytotoxic T lymphocytes carrying the CD8 antigen, which limit the establishment of metastases. Neutralization of IL-17 or G-CSF and absence of cd T cells prevents neutrophil accumulation and downregulates the T-cell-suppressive phenotype of neutrophils. Moreover, the absence of cd T cells or neutrophils profoundly reduces pulmonary and lymph node metastases without influencing primary tumour progression. Our data indicate that targeting this novel cancer-cell-initiated domino effect within the immune system-the cd T cell/IL-17/neutrophil axis-represents a new strategy to inhibit metastatic disease.
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In patients with breast cancer, increased neutrophil abundance predicts worsened metastasis-specific survival 3, 4 . Currently, the role of neutrophils in metastasis is controversial, since both pro-and antimetastatic functions have been described [5] [6] [7] . We found a profound systemic expansion of neutrophils in mammary tumour-bearing K14cre; Cdh1 F/F ;Trp53 F/F (KEP) mice 8 , compared with wild-type (WT) littermates (Extended Data Fig. 1a, b) . Neutrophils, defined as CD45 
F4/80
2 cells, accumulated throughout every organ examined (Extended Data Fig. 1c, d ). We also investigated our recently described KEP-based model of spontaneous breast cancer metastasis 9 ( Fig. 1a) , where systemic neutrophil expansion was observed as well ( Fig. 1b and Extended Data Fig. 1e, f) . Neutrophil expansion was tumour-induced, because surgical removal of the primary tumour resulted in their immediate reduction (Extended Data Fig. 1g ).
To determine the functional significance of neutrophils in metastasis, neutrophils were depleted using anti-Ly6G antibodies (Extended Data Fig. 2a-c) . Treatment was initiated when tumours were palpable and continued until mice developed overt metastatic disease. Neutrophil depletion did not influence tumour growth (Extended Data Fig. 2d ), tumour histopathology (Extended Data Fig. 2e ) or microvessel density (Extended Data Fig. 2e, f) . In contrast, neutrophil depletion resulted in significant reduction in both pulmonary and lymph node metastasis (Fig. 1c) . These data indicate that neutrophils assist the spread of cancer cells to multiple locations.
Next, we evaluated the role of neutrophils in different phases of the metastatic cascade. Neutrophils were depleted during primary tumour growth (early phase) or after removal of the primary tumour (late phase) (Fig. 1a) . Interestingly, neutrophil depletion decreased multi-organ metastasis in the early phase, but not the late phase (Fig. 1d ). Metastatic nodule size was not affected (Extended Data Fig. 2g ), suggesting that neutrophils facilitate multi-organ metastasis during the early steps of the metastatic cascade.
To understand the mechanism by which neutrophils facilitate metastasis, their phenotype was investigated. Previous reports identified the haematopoietic stem cell marker cKIT on pro-metastatic myeloid cells 6, [10] [11] [12] , and CD11b
1

VEGFR1
1 cells have been implicated in the pre-metastatic niche 10, 13, 14 . A greater proportion of neutrophils from tumour-bearing KEP mice expressed cKIT, while both neutrophils and monocytes from WT and KEP mice expressed VEGFR1 (Extended Data Fig. 3a, b) . In the metastasis model, cKIT 1 neutrophils also expanded systemically, as tumours grew larger (Extended Data Fig. 3c ) and reduced to baseline levels after tumour resection (Extended Data Fig. 3d ). Nuclear morphological analysis revealed characteristics of immature cells 15 , including banded, circular and non-segmented nuclei, whereas most WT neutrophils appeared hyper-segmented (Extended Data Fig. 3e ), suggesting that KEP mammary tumours promote the release of immature neutrophils into circulation.
Next-generation RNA sequencing (RNA-seq) was performed on circulating neutrophils from WT and tumour-bearing KEP mice, revealing 100 differentially expressed genes (Extended Data Fig. 4a and Extended Data Table 1 ). Several genes upregulated in neutrophils from KEP mice, including Prok2 (also known as Bv8), S100a8 and S100a9 (Fig. 2a) , have previously been linked to metastasis 6, 14 . Nos2, the gene encoding inducible nitric oxide synthase (iNOS), was the most strongly upregulated gene, by more than 150-fold (Fig. 2a) . Because iNOS suppresses T cells [16] [17] [18] , we hypothesized that neutrophils promote metastasis via immunosuppression. Indeed, neutrophils from KEP mice inhibited the CD3/CD28-induced proliferation of naive splenic CD8 1 T cells ex vivo compared with WT neutrophils, and an iNOS inhibitor reversed this effect (Fig. 2b and Extended Data Fig. 4b ). In lungs of control and neutrophil-depleted tumour-bearing mice, the proportions of CD8 1 T cells did not differ (Extended Data Fig. 4c ). However, the effector phenotype of CD8 1 T cells was markedly enhanced upon neutrophil depletion, as evidenced by a significantly greater proportion of CD62L
2
CD44
1 and interferon-c 1 (IFN-c 1 ) cells ( Fig. 2c and Extended Data Fig. 4d, e) . To establish further a mechanistic link between neutrophils and CD8
1 T cell activity, we depleted both cell populations in the metastasis model. Combined depletion of neutrophils and CD8 (Fig. 2d) , without affecting primary tumour growth (Extended Data  Fig. 4f ). Depletion of CD8 1 T cells alone did not alter tumour growth or multi-organ metastasis (data not shown). These data suggest that neutrophils facilitate cancer cell spread by suppressing CD8 1 T cells. As such, neutrophils in the KEP model can be categorized as a subpopulation of myeloid-derived suppressor cells 15 . We then asked how mammary tumours induce systemic neutrophil expansion. Cytokine profile comparison of WT mammary glands and KEP mammary tumours showed that granulocyte-macrophage colonystimulating factor (GM-CSF) and G-CSF levels-two key regulators of neutrophil biology 19 -were not significantly increased in KEP tumours (Extended Data Fig. 5a, b) . However, expression of IL-1b, IL-6 and IL12p40, a subunit of IL-23, was increased (Extended Data Fig. 5a, b) . These cytokines are known to stimulate IL-17 from lymphocytes [20] [21] [22] [23] .
In inflammatory diseases such as psoriasis, lymphocyte-derived IL-17 regulates neutrophil expansion via systemic induction of G-CSF 21, 22, 24 . We hypothesized that the same inflammatory cascade is important in breast cancer metastasis. Indeed, serum levels of IL-17A and G-CSF were higher in tumour-bearing KEP mice than in WT mice (Fig. 3a) . Neutralization of IL-17A in tumour-bearing KEP mice decreased G-CSF serum levels, while G-CSF blockade did not affect IL-17A levels (Fig. 3a) , indicating that IL-17 is upstream of G-CSF. Inhibition of either cytokine reduced circulating neutrophils, lowered cKIT 1 neutrophil proportions ( Fig. 3b ) and reversed neutrophil phenotype (Fig. 3c) . Injection of recombinant G-CSF to anti-IL-17-treated tumour-bearing KEP mice overcame the effects of anti-IL-17 treatment (Extended Data Fig. 5c-e) . Additionally, treatment of WT mice with recombinant G-CSF resulted in neutrophil expansion, increased presence of cKIT 1 neutrophil proportions and changed neutrophil phenotype (Extended Data Fig. 5c-e ). These data demonstrate a requirement for the IL-17/G-CSF signalling cascade in both neutrophil expansion and phenotype.
Next, we determined the source of IL-17. As T cells are known to produce IL-17 (refs 20, 21, 23) , splenic CD3 1 T cells were analysed using a T cell-specific gene expression array. This analysis validated upregulation of IL-17-related cytokines in T cells from tumour-bearing KEP mice (Extended Data Fig. 5f ). We then asked whether lymphocytes are the only source of IL-17 and whether they drive metastasis. KEP mice were crossed with Rag1 2/2 mice, which lack T and B cells. Tumour initiation, proliferation and histology were the same between KEP;Rag1 1/2 and KEP;Rag1 2/2 mice (Extended Data Fig. 6a and data not shown). However, KEP;Rag1 2/2 mice exhibited lower levels of IL-17A and G-CSF in serum (Fig. 3d) , decreased neutrophil counts (Fig. 3e ) and altered neutrophil phenotype (Fig. 3f) . Transforming growth factor b1 (TGFb1) levels were unchanged between KEP;Rag1 1/2 and KEP;Rag1 2/2 mice (Extended Data Fig. 6b ), suggesting that, unlike other models 25 , TGF-b plays a lesser role in modulating neutrophil phenotype than IL-17-induced G-CSF. Importantly, KEP;Rag1 2/2 mice displayed less pulmonary and lymph node metastases (Fig. 3g) . Metastases develop in 100% of recipient mice. Antibody-mediated depletion experiments were performed in three ways: from palpable tumours to metastasis-related death (continuous treatment), during primary tumour growth (early phase) or after surgery until metastasis-related death (late phase). b, Neutrophil proportions in lungs at the indicated tumour size (n 5 6, 5, 6 and 8 mice for 0, 9, 25 and 100 mm 2 , respectively; Kruskal-Wallis test followed by post-hoc Dunn's test). c, d, Images of cytokeratin 8-stained lung sections, quantification of lung metastases and incidence of metastasis in lymph nodes. Neutrophils were depleted continuously until metastasis-related death in c (n 5 11 mice per group; Mann-Whitney U-test and Fisher's exact test) or depleted during the early or late phases in d (n 5 9 control, 11 early phase, 14 late phase; Kruskal-Wallis test followed by post-hoc Dunn's test and Fisher's exact test). Data in d are representative of two independent experiments. All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001. Scale bars, 6 mm. 1 T cell proliferation was measured. c, CD8
1 T cell activation status in lungs of transplanted tumour-bearing control and neutrophil-depleted mice (n 5 6 per group). d, Quantification of lung metastases and incidence of lymph node metastasis following neutrophil and CD8
1 T cell depletion (n 5 11 control, 16 anti-Ly6G, 8 anti-Ly6G/CD8; Kruskal-Wallis test followed by post-hoc Dunn's test and Fisher's exact test). All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001.
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G2015 Macmillan Publishers Limited. All rights reserved where Rag1 2/2 mice were recipients of transplanted KEP tumour fragments, resulting in reduced pulmonary metastasis (Extended Data Fig. 6c ). Thus, IL-17-producing lymphocytes drive neutrophil accumulation, phenotype and metastasis.
Direct ex vivo intracellular cytokine staining was performed to determine which T lymphocyte subset produces IL-17. Both CD4
1 T cells and cd T cells expressed IL-17A (Fig. 4a) , and both IL-17-producing subpopulations were increased in various organs of tumour-bearing KEP mice compared with WT mice (Fig. 4b and Extended Data Fig. 7a ). In primary tumours, the abundance of cd and CD4
1 T cells was too low (,0.2% and ,2% of all live cells, respectively) to assess IL-17 expression reliably. cd T cells exhibited higher IL-17A levels than CD4 1 T cells ( Fig. 4a and Extended Data Fig. 7b ). Both cell populations were depleted to determine their functional importance. CD4
1 T cell depletion lowered cKIT 1 neutrophils, but failed to influence total neutrophil expansion, IL-17A or G-CSF levels (Extended Data Fig. 7c -e). Conversely, depletion of cd T cells decreased IL-17A and G-CSF serum levels ( Fig. 4c) , reduced circulating neutrophils, lowered cKIT 1 neutrophil proportions ( Fig. 4d and Extended Data Fig. 7c ) and reversed neutrophil phenotype (Fig. 4e ). These data indicate that IL-17-producing cd T cells promote neutrophil expansion and phenotypic alterations. IL-17-producing cd T cells in tumour-bearing KEP mice were CD27 2 , mostly Vc4
1
, and a proportion expressed CCR6, IL-1R1 and ROR-ct (Extended Data Fig. 8a , b) similar to other inflammatory diseases 21 .
We then asked how KEP mammary tumours activate IL-17-producing cd T cells. On the basis of literature [20] [21] [22] [23] and cytokine analysis (Extended Data Fig. 5a , b), we focused on IL-23 and IL-1b. IL-17A expression by cd T cells, G-CSF serum levels and neutrophil expansion was decreased by neutralization of IL-1b, but unaffected by inhibition of IL-23 ( Fig. 4f-h ). Macrophages were the most abundant IL-1b-expressing cell type in KEP tumours (Extended Data Fig. 8c, d ). These data provide a mechanistic link between mammary tumours and cd T cells.
Depletion of cd T cells in the early phase of the metastasis model did not affect tumour histopathology, microvessel density or primary tumour , 32 KEP;Rag1 2/2 mice). All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001 as determined by Mann-Whitney U-test or Fisher's exact test. . c, Cytokine levels in serum of control (n 5 10) and anti-cdTCR-treated (n 5 7) KEP mice. d, Proportions of circulating neutrophils and cKIT-expressing neutrophils in KEP mice during primary tumour growth (n 5 8 per group). e, Gene expression in circulating neutrophils from tumour-bearing KEP control mice (n 5 10) and anti-cdTCR-treated KEP mice (n 5 6). f, Proportion of IL-17A-producing cd T cells in tumour-bearing mice (n 5 6 KEP control, 5 anti-IL-23p19, 5 anti-IL-1b). g, Cytokine levels in serum (n 5 9 KEP control, 5 anti-IL-23p19, 6 anti-IL-1b). h, Proportions of circulating neutrophils and cKIT-expressing neutrophils in KEP mice during primary tumour growth (n 5 9 control, 5 anti-IL-23p19, 5 anti-IL-1b). i, j, Quantification of lung metastases and incidence of lymph node metastasis in the metastasis model (n 5 10 control, 9 anticdTCR-treated mice; n 5 9 per group Tcrd 1/2 and Tcrd 2/2 mice). All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001 as determined by Mann-Whitney U-test or Fisher's exact test.
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G2015 Macmillan Publishers Limited. All rights reserved growth (Extended Data Fig. 8e and data not shown) . Importantly, however, pulmonary and lymph node metastases were significantly decreased in cd T cell-depleted mice (Fig. 4i) . These data were validated with Tcrd 2/2 mice, which lack cd T cells. KEP tumour fragments were orthotopically transplanted into Tcrd 1/2 and Tcrd 2/2 mice and resected after outgrowth. Genetic elimination of cd T cells also resulted in a significant reduction in pulmonary metastasis (Fig. 4j) without affecting primary tumour growth (Extended Data Fig. 8f) . These data confirm a pro-metastatic role for cd T cells.
In summary, we show that mammary tumour-induced, IL-17-producing cd T cells drive systemic expansion and polarization of neutrophils towards a CD8
1 T cell-suppressive phenotype and subsequent metastasis formation in distant organs (Extended Data Fig. 9 ). The importance of neutrophils during the early steps of the metastatic cascade and the upregulation of Prok2, S100a8 and S100a9 in neutrophils suggest that neutrophils may help to establish the pre-metastatic niche 6, 10, 14 ; however, the role of these neutrophil-derived factors and others remains to be established in the KEP model. In patients with breast cancer, independent clinical studies consistently point towards a pro-metastatic role for neutrophils, cd T cells and IL-17 (refs 3, 4, 26-29) . Here, we establish a mechanistic connection between these independent clinical observations. In infection and inflammatory disorders, the cd T cell/IL-17/neutrophil axis drives disease pathogenesis 21, 23, 30 . We now demonstrate that this targetable pathway also perpetuates breast cancer metastasis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . The onset of mammary tumour formation was monitored twice weekly by palpation and calliper measurements starting at 4 months of age. Tcrd 2/2 mice on the FVB/N background were a gift from A. Hayday 33 . The spontaneous metastasis model has also been described 9 . Briefly, this model is based on the orthotopic transplantation of KEP tumour pieces into 10-to 12-week-old female recipient FVB/N mice, Rag1 2/2 mice, Tcrd 1/2 or Tcrd 2/2 mice. These tumour pieces are allowed to grow out, then surgically removed at 100 mm 2 , after which 100% of mice develop overt metastatic disease.
To deplete immune cells or neutralize cytokines, mice were injected intraperitoneally with an initial 400 mg followed by 100 mg thrice weekly for anti-Ly6G (clone 1A8; BioXCell), 200 mg twice weekly for anti-CD8 (clone 2.43; BioXCell) or 100 mg twice weekly for anti-cdTCR (clone GL3; purified by the NKI protein facility). For cytokine neutralization experiments, KEP mice were injected intraperitoneally with 50 mg twice weekly for anti-IL-17A (clone 17F3; BioXCell), 50 mg thrice weekly for anti-G-CSF (clone 67604; R&D Systems), 50 mg twice weekly anti-IL-23p19 (clone G23-8; eBioscience) or 50 mg twice weekly anti-IL-1b (clone B122; BioXCell). Control mice received equal amounts of isotope control antibodies or equal volumes of PBS. Where indicated, WT and KEP mice were injected intraperitoneally with 5 mg rG-CSF (Peprotech) for four consecutive days and were killed on the fifth day. Tumour-bearing KEP mice injected with rG-CSF received anti-IL-17 at the same schedule as above. Antibody injections began when KEP mammary tumours reached 25 mm 2 until death at 225 mm 2 , or transplanted tumours reached 9 mm 2 where indicated until surgery at 100 mm 2 . Three independent KEP donor tumours were tested in neutrophil depletion experiments resulting in the same outcome. One of these donor tumours was used throughout the remainder of the study. Blood samples were taken before and during antibody injections for flow cytometry analyses. Animals were randomized before beginning the treatment schedule. Mice were kept in individually ventilated and open cages, and food and water were provided ad libitum. Animal experiments were approved by the Animal Ethics Committee of the Netherlands Cancer Institute and performed in accordance with institutional, national and European guidelines for Animal Care and Use. Immunohistochemistry. Formalin-fixed tissues were processed by routine procedures. Haematoxylin and eosin staining was performed as described 9 . Citrate antigen retrieval was used for all staining procedures. Neutrophils were detected using either anti-Ly6B (clone 7/4; Cedarlane) or anti-Ly6G (clone 1A8; BD Biosciences), when primary tumours reached 100 mm 2 . Quantitative analysis of neutrophil abundance was performed by counting cells in five high-power (340) fields of view (FOV) per tissue. Metastases were detected using anti-cytokeratin 8 (clone Troma 1; Developmental Studies Hybridoma Bank, University of Iowa). In the metastasis model, the total number of cytokeratin 8 1 nodules was scored in one lung section of each animal. The size of each nodule was measured using ImageJ, then represented as arbitrary units. Lymph node metastases were scored as positive or negative on the basis of the presence of cytokeratin 8 1 metastases. Mice that developed overt metastatic disease (that is, respiratory distress or 225 mm 2 axillary lymph node metastasis) were included in the analysis; mice that were killed as a result of local recurrence were excluded. Vimentin, E-cadherin and CD34 staining was performed as previously described 9 and scored independently by two blinded researchers. Microvessel density was scored by averaging the total number of blood vessels from five fields of view for each tumour section. For metastasis quantification in K14cre;Cdh1 ;Rag1 2/2 mice, single lung or lymph node sections were scored as positive or negative on the basis of the presence of cytokeratin 8 1 metastases. Stained slides were digitally processed using the Aperio ScanScope and captured using ImageScope software version 11.0.2. Brightness and contrast for representative images were adjusted equally among groups. Flow cytometry and intracellular staining. Tissues were collected in ice-cold PBS. Blood samples were collected in tubes containing heparin. Tumours and lungs were mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory Engineering). Tumours were digested for 1 h at 37 uC in 3 mg ml 21 collagenase type A (Roche) and 25 mg ml 21 DNase (Sigma) in serum-free DMEM medium. Lungs were digested for 30 min at 37 uC in 100 mg ml 21 Liberase TM (Roche). Enzyme activity was neutralized by addition of cold DMEM/8% FCS and suspension was dispersed through a 70 mm cell strainer. Spleen, lymph nodes and liver were mashed through a 70 mm cell strainer. All single-cell suspensions were treated with NH 4 Cl erythrocyte lysis buffer. Cells were stained with directly conjugated antibodies (listed below) for 30 min at 4 uC in the dark in PBS/1% BSA. 7AAD (1:20; eBioscience) or Fixable Viability Dye eFluor 780 (1:1,000; eBioscience) was added to exclude dead cells. For intracellular staining, single-cell suspensions were stimulated in IMDM containing 8% FCS, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin, 0.5% b-mercaptoethanol, 50 ng ml 21 PMA, 1 mM ionomycin and (1:1,000) Golgi-Plug (BD Biosciences) for 3 h at 37 uC. Surface antigens were stained first, followed by fixation and permeabilization using the Cytofix/Cytoperm kit (BD Biosciences), then staining of intracellular proteins. All experiments were performed using a BD LSRII flow cytometer using Diva software. Data analyses used FlowJo Software version 9.7.1. Median fluorescence intensity of IL-17A expression was calculated after gating on IL-17 1 cells within individual T cell subsets. All antibodies were purchased from eBioscience, except Ly6G-AlexaFluor 700, CCR6 and Vc1 from BioLegend, and VEGFR1, CCR2, IL-23R and IL-1R1 from R&D Systems. The following antibodies were used in these experiments.
Myeloid 
Ly6C
1 cells. Giemsa staining. Blood was collected by tail vein puncture in heparin-coated tubes. Red blood cells were lysed with NH 4 Cl lysis buffer. White blood cells were smeared onto glass slides then stained with decreasing concentrations of WrightGiemsa solution. RNA-seq. Ly6G 1 neutrophils were isolated by magnetic column (Miltenyi) from blood of mice. KEP mice with mammary tumours around 225 mm 2 in size and age-matched WT mice were used. Purity of isolated neutrophils was validated by flow cytometry and only samples greater than 90% purity were used. RNA was isolated using Trizol and then treated with DNase I (Invitrogen). Samples were put over a Qiagen RNeasy column for cleanup. RNA quality was confirmed with a 2100 Bioanalyzer from Agilent. RNA-Seq libraries were prepared using the reagents provided in the Illumina TruSeq RNA Sample Preparation Kit, following the manufacturer's protocol. Libraries were PCR amplified for 12 cycles and sequenced on an Illumina HiSeq 2000 System with TruSeq reagent kits and software, generating paired-end 51 base-pair reads. Sequence reads were aligned to the mouse reference genome (National Center for Biotechnology Information build 37) using TopHat. HTSeq-count was then used to generate a list of the total number of uniquely mapped reads for each gene and sample. Sequence reads were normalized to 10 million reads per sample and log 2 transformed with the formula, log 2 (((expression gene X 4 library size)10 6 )11), where the library size was the sum of all expression values per sample. To determine which genes were differentially expressed between samples, the R package Limma was used. Absolute gene expressions were used as input and genes with no expression in any sample were removed from the data set. Voom was used to transform the count data to log 2 counts per million and estimation of the variance. The P value was set to a cut-off of 0.05, resulting in 100 significant, differentially expressed genes. Unsupervised clustering was performed on these 100 genes and the data were transformed into a heat-map.
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Real-time PCR. Neutrophil RNA was extracted as above then converted to complementary DNA (cDNA) with an AMV reverse transcriptase using Oligo(dT) primers (Invitrogen). cDNA (20 ng per well) was analysed by SYBR green realtime PCR with 500 nM primers using a LightCycler 480 thermocycler (Roche). b-actin was used as a reference gene. The following primer sequences were used for each gene: Nos2 forward 59-GTTCTCAGCCCAACAATACAAGA-39, reverse 59-GTGGACGGGTCGATGTCAC-39; Prok2 forward 59-CTTCGCCCTTCTTCTT TCCT-39, reverse 59-GCATGTGCTGTGCTGTCAGT-39; S100a8 forward 59-T GAGCAACCTCATTGATGTCTACC-39, reverse 59-ATGCCACACCCACTTTT ATCACC-39; S100a9 forward 59-GAAGAAAGAGAAGAGAAATGAAGCC-39; reverse 59-CTTTGCCATCAGCATCATACACTCC-39; Il1b forward 59-CAACC AACAAGTGATATTCTCCATG-39, reverse 59-GATCCACACTCTCCAGCTG CA-39; Actb forward 59-CCTCATGAAGATCCTGACCGA-39, reverse 59-TTT GATGTCACGCACGATTTC-39. Fold change was calculated using the formula 2
. T cell proliferation assay. Blood neutrophils from WT mice and splenic CD8 1 T cells from WT mice were isolated by magnetic column (Miltenyi). Blood neutrophils from KEP mice with mammary tumours around 225 mm 2 in size were also used. CD8
1 T cells were labelled with Cell Trace CFSE following the manufacturer's instructions (Invitrogen). Equal numbers of cells (2 3 10 5 ) were co-cultured in a 96-well flat bottom plate. CD3/CD28 Dynabeads (Invitrogen) were added according to manufacturer's instruction, and the iNOS inhibitor, L-NMMA (Sigma), was added at 0.5 mM where indicated. After 48 h, T cell proliferation was evaluated on a BD LSRII flow cytometer using Diva software using the following antibodies: CD8a-PE (1:600; clone 53-6.7), CD11b-APC (1:400; clone M1/70), Ly6C-eFluor 450 (1:400; clone HK1.4), Ly6G-AlexaFluor 700 (1:400; clone 1A8) and 7AAD viability marker. Data analyses used FlowJo Software version 9.7.1. Proliferation index was calculated using the formula (percentage of proliferated, co-cultured CD8 1 T cells)/(perentage of proliferated CD8 1 T cells without co-culture) 3 100, for each replicate experiment.
Cytokine analysis. Multiplex quantification of cytokines and chemokines in mammary glands and tumours was performed using the premixed 24-plex Bio-Plex Pro Mouse Cytokine Assay (Bio-Rad) according to the manufacturer's recommendations. Protein lysates were prepared as previously described 34 . Unsupervised clustering was performed on normalized, median-centred data then converted to a heat-map using Genesis software. For IL-17A and G-CSF serum levels, BD Cytometric Bead Arrays were used as directed and analysed on a Cyan flow cytometer with Summit software (Beckman Coulter). Data analyses used FlowJo Software version 9.7.1. For TGF-b1, a DuoSet ELISA kit was purchased from R&D Systems and performed according to the manufacturer's instructions. PCR array. The spleens of three WT or KEP mammary tumour-bearing mice were pooled and labelled with anti-CD3 antibodies. CD3
1 T cells were sorted using a BD FACSAria II. RNA was isolated with Trizol as above. Gene expression differences were analysed using a mouse T cell-specific PCR array from Qiagen according to their instructions and software. Genes exhibiting a threefold change were considered biologically relevant. Statistical analysis. Data analyses used GraphPad Prism version 7. Applied analyses are indicated in corresponding legends. No statistical methods were used to predetermine sample sizes. Sample sizes were based on previous experience with the models 9, 32, 34 . Differences with P , 0.05 were considered statistically significant. 1 cells. Neutrophils were not detectable in WT mammary glands (n 5 5 WT, 7 KEP mice). e, Representative images of Ly6G-stained lung sections and quantification of neutrophil accumulation in the metastasis model. Data were generated from mock-transplanted, non-tumour-bearing mice (0 mm 2 ), or tumour-transplanted recipient mice killed when tumours reached the tumour size shown or when mice exhibited signs of respiratory distress due to pulmonary metastasis. For quantification in lungs with metastases, neutrophils residing inside metastases were excluded. T, pulmonary metastatic lesion. Scale bar, 100 mm (n 5 3, 5, 6, 6 and 3 mice for 0, 9, 25, 100 mm 2 and metastasis respectively). f, Kinetics of neutrophil accumulation in various organs of the metastasis model by flow cytometry after gating on CD45 1 cells. Recipient mice transplanted with KEP tumour pieces were killed at the tumour size shown (n 5 6, 5, 6, and 7 mice for 0, 9, 25, 100 mm 2 respectively). g, Kinetics of neutrophil proportions in blood (gated on CD45 1 cells), before and after surgical removal of their primary tumour (n 5 5). All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001 as determined by Mann-Whitney U-test or Kruskal-Wallis test followed by post-hoc Dunn's test. 
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2 cells), before and after surgical removal of the primary tumour (n 5 5 per group; Mann-Whitney U-test). e, Representative images and quantification of neutrophil nuclear morphology. Ly6G 1 cells were isolated from blood of WT and tumour-bearing KEP mice then assessed by Giemsa stain. Hypersegmented cells were considered mature, whereas all other cells were considered immature. Scale bar, 10 mm. (n 5 6 WT, 5 KEP mice; MannWhitney U-test). All data are mean 1 s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001.
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Extended Data Figure 4 | Neutrophils influence the function and phenotype of CD8 1 T cells. a, Unsupervised hierarchical clustering of RNA-Seq analysis depicting 100 differentially expressed genes between circulating neutrophils from WT and tumour-bearing KEP mice. P value (0.05) was used as cutoff (n 5 4 WT, 5 KEP mice). See also Extended Data Table 1 
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Extended Data Figure 9 | The cd T cell/IL-17/neutrophil axis promotes breast cancer metastasis. Mammary tumours evoke a systemic inflammatory cascade that is initiated by IL-1b production. Tumour-derived IL-1b activates cd T cells to produce IL-17. Increased systemic IL-17 levels lead to upregulation of G-CSF, which subsequently causes neutrophil expansion and alteration of neutrophil phenotype. These phenotypically altered neutrophils produce iNOS that suppresses the activity of anti-tumour CD8 1 T cells. As a result of this systemic inflammatory cascade, the chance that disseminated cancer cells can establish metastases in distant organs is maximized.
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